In a new study published in Pharmacopsychiatry, Crocus sativus L. versus
citalopram in the treatment of major depressive disorder with anxious distress: a double - blind, controlled clinical trial, saffron (Crocus sativus L.) has been shown to have both antidepressant and antianxiety effects.
The proportion of mothers who used other SSRI drugs than
citalopram in the study data was relatively low, meaning that the study's findings regarding other SSRIs can not be considered reliable.
Not exact matches
Promisingly, another drug called imipramine, which belongs to the second main class of antidepressants, had similar effects on miRNA - 1202 to
citalopram, when applied to neurons grown
in the lab.
Blood samples taken from people about to start treatment with
citalopram, one of the most widely used SSRIs — a class of antidepressant — showed that those who subsequently improved
in response to the drug had about half the levels of miRNA - 1202 as those who failed to respond.
«Vortioxetine
in depression: No hint of added benefit: Inadequate limitation of the study pool for the indirect comparison with
citalopram.»
It identified 14 studies with vortioxetine and 10 with
citalopram, but included only 3 and 4 of these studies
in the meta - analysis.
The researchers gauged serotonergic neurotransmission by measuring its response to
citalopram, a drug that stalls serotonin molecules
in the synaptic gap (as measured by the hormone prolactin's response to
citalopram.
Their study, published online today
in the journal Nature, provides fresh insight into how
citalopram and paroxetine, two of the most widely prescribed selective serotonin reuptake inhibitors, or SSRIs, interact with and inhibit serotonin transport.
Among the SSRI drugs analysed
in the study, children of mothers who used
citalopram during pregnancy had longer umbilical cords than others.
In order to examine the «placebo breaking the blind» theory, a research group at the Sahlgrenska Academy in Gothenburg, Sweden, has now analyzed data from the clinical trials that were once undertaken to establish the antidepressant efficacy of two of the most commonly used SSRIs, paroxetine and citalopra
In order to examine the «placebo breaking the blind» theory, a research group at the Sahlgrenska Academy
in Gothenburg, Sweden, has now analyzed data from the clinical trials that were once undertaken to establish the antidepressant efficacy of two of the most commonly used SSRIs, paroxetine and citalopra
in Gothenburg, Sweden, has now analyzed data from the clinical trials that were once undertaken to establish the antidepressant efficacy of two of the most commonly used SSRIs, paroxetine and
citalopram.
Those amounts nearly doubled
in people who took
citalopram: They were generally more averse to causing harm, but still preferred profiting from their own pain over another's, Crockett's team reports online today
in Current Biology.
In order to examine the «placebo breaking the blind» theory, a research group at the Sahlgrenska Academy, has now analyzed data from the clinical trials that were once undertaken to establish the antidepressant efficacy of two of the most commonly used SSRIs, paroxetine and
citalopram.
Behavioral profile
in comparison with venlafaxine, reboxetine,
citalopram, and clomipramine.
In another study of patients with social phobia that compared the effects of CBT and the antidepressant citalopram, both treatments triggered changes in the parts of the brain that help us process, and act upon, fear
In another study of patients with social phobia that compared the effects of CBT and the antidepressant
citalopram, both treatments triggered changes
in the parts of the brain that help us process, and act upon, fear
in the parts of the brain that help us process, and act upon, fears.
60 participants finished the study and they all showed significant improvement
in depression and anxiety scores, with no significant difference
in effectiveness or side effects from either the saffron or
citalopram.
[PMID 19996755] Serotonin transporter triallelic genotype and response to
citalopram and risperidone
in dementia with behavioral symptoms.
In the present case, the generic undertakings had begun making preparations to enter the
citalopram market one to three years before the expiry of Lundbeck's original patents (para 179).
Lundbeck's compound patent for
citalopram had expired by January 2002
in most EEA countries, but the company held certain process patents which did not constitute insurmountable barriers to entry for generic producers.
This is so because even if Lundbeck's process patents were presumed to be valid, they did not allow the exclusion of all competition
in relation to
citalopram (para 435).
The main purpose of this study was to improve mood and behavior disorders
in RTT patients with venlafaxine (SNRI), and compare the results with
citalopram (SSRIs) during 6 - 8 weeks, to determine which drug offered greater efficacy and fewer side effects, as well as to compare them to risperidone, and to correlate cortisol levels
in saliva with stress and drug response.
Those not remitting with or intolerant of
citalopram could receive subsequent treatment steps provided
in an equipose randomized design described elsewhere.17
Objective To document the short - term efficacy of a selective serotonin reuptake inhibitor (
citalopram) and interpersonal psychotherapy (IPT)
in reducing depressive symptoms
in patients with CAD and major depression.